Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX/mFOLFIRI plus targeted therapy in first-line advanced colorectal cancer
ChiCTR2400088021Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Aug 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, levoleucovorin, oxaliplatin and irinotecan in colorectal cancer (CRC), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: objective response rate. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
fluorouracillevoleucovorinoxaliplatinirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400088021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088021.